FSD Pharma submits Phase-1 Multiple Ascending Doses trial application for neuroprotective drug Lucid-21-302 to Australian ethics committee.

FSD Pharma has submitted a Phase-1 Multiple Ascending Doses clinical trial application for its compound Lucid-21-302, a neuroprotective drug, to an Australian human ethics review committee. The trial aims to evaluate the safety and pharmacokinetics of the compound in healthy adults. The application follows a completed Phase-1 Single Ascending Dose trial.

May 07, 2024
3 Articles